NASDAQ · WHWK
Healthcare · Biotechnology
$4.19
Down-$0.20 (-4.56%)
Updated Sep 10, 2026, 1:02 PM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance
1M range · 20 trading sessions · Daily adjusted prices
WHWK closed at $4.19 after 20 trading sessions, down 11.04% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Sep 9, 2026 | $4.39 | $4.4899 | $4.16 | $4.19 | 168.32K |
| Sep 8, 2026 | $4.56 | $4.6107 | $4.37 | $4.39 | 161.01K |
| Sep 4, 2026 | $4.59 | $4.65 | $4.53 | $4.60 | 178.14K |
| Sep 3, 2026 | $4.71 | $4.77 | $4.58 | $4.63 | 223.09K |
| Sep 2, 2026 | $4.66 | $4.81 | $4.53 | $4.71 | 138.97K |
| Sep 1, 2026 | $4.49 | $4.755 | $4.4409 | $4.63 | 202.77K |
| Aug 31, 2026 | $4.57 | $4.59 | $4.44 | $4.54 | 359.27K |
| Aug 28, 2026 | $4.87 | $5.0304 | $4.60 | $4.62 | 100.07K |
| Aug 27, 2026 | $4.83 | $4.9799 | $4.83 | $4.87 | 312.9K |
| Aug 26, 2026 | $5.08 | $5.10 | $4.83 | $4.84 | 136.26K |
| Aug 25, 2026 | $4.89 | $5.085 | $4.8891 | $5.08 | 167.97K |
| Aug 24, 2026 | $4.74 | $4.90 | $4.5406 | $4.88 | 240.09K |
| Aug 21, 2026 | $4.87 | $4.94 | $4.64 | $4.73 | 226.21K |
| Aug 20, 2026 | $4.83 | $4.93 | $4.71 | $4.83 | 293.37K |
| Aug 19, 2026 | $4.81 | $5.00 | $4.73 | $4.87 | 328.24K |
| Aug 18, 2026 | $4.59 | $4.82 | $4.59 | $4.76 | 151.6K |
| Aug 17, 2026 | $4.45 | $4.715 | $4.45 | $4.64 | 335.3K |
| Aug 14, 2026 | $4.68 | $4.68 | $4.41 | $4.46 | 274.48K |
| Aug 13, 2026 | $4.72 | $4.81 | $4.675 | $4.68 | 317.8K |
| Aug 12, 2026 | $4.65 | $4.785 | $4.50 | $4.71 | 310.89K |
The latest Smart Investors Daily articles mentioning WHWK.
WHWK research
Company profile and research snapshot.
Whitehawk Therapeutics Inc is a preclinical stage oncology therapeutics. The company is engaged in applying technologies to established tumor biology to efficiently deliver improved cancer treatments. The company's three-asset ADC portfolio is engineered to overcome the limitations of first-generation predecessors to deliver a meaningful impact for patients with difficult-to-treat cancers.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Jul 13, 2026 | Leerink Partners | Outperform | — |
| Jun 25, 2026 | B. Riley Securities | Buy | — |
| Apr 16, 2026 | Citizens | Market Outperform | — |
| Dec 22, 2025 | Jones Trading | Buy | — |
No generated briefing is available yet.
Yahoo · Sep 2, 2026
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently develop improved antibody drug conjugate (ADC) cancer treatments, today announced participation at the following investor conferences:
Yahoo · Aug 28, 2026
Does Whitehawk Therapeutics, Inc. (WHWK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Yahoo · Aug 13, 2026
AKTX-101 advancing through IND-enabling development activities toward planned initiation of Phase 1 clinical trial in mid-2027 Compelling ASCO 2026 preclinical data further differentiates PH1 mechanism in KRAS-mutated pancreatic cancer models Strategic research collaboration with Whitehawk Therapeutics expands potential application of Akari’s PH1 platform into dual-payload ADCs Balance sheet strengthened by approximately $8.6 million of financing during the quarter, led by long-term strategic in
Yahoo · Aug 6, 2026
Whitehawk Therapeutics, Inc. (Nasdaq: WHWK), a clinical-stage oncology therapeutics company applying advanced technologies to established tumor biology to efficiently deliver improved antibody drug conjugate (ADC) cancer treatments, today announced financial results for the quarter ended June 30, 2026, and provided recent corporate highlights.
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning WHWK.
